Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 11Tumor-Agnostic 3Thoracic 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

Dexamethasone 315Bortezomib 166Lenalidomide 132pomalidomide 113daratumumab 96carfilzomib 69Cyclophosphamide 44Calcium Dobesilate 41belantamab mafodotin 32elotuzumab 31fludarabine 27ixazomib 24isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × napabucasin × Plasma cell × Clear all
NCT02352558 2023-11-14

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Sumitomo Pharma America, Inc.

Phase 1 Completed
15 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡